Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia

Stock Information for Larimar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Larimar Therapeutics Inc.

Century Therapeutics Appoints Joseph Truitt to Board of Directors
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Biotech and Big Tech Drive the Morning Narrative
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.